In a 48-week Phase 2 obesity trial, participants on the 12mg dose recorded a mean body-weight reduction of 24.2%, versus 2.1% on placebo[1]. 83% of that group lost 15% or more of their body weight, and 93% lost at least 10%[1]
A proportion of participants in the retatrutide trial discontinued treatment due to gastrointestinal side effects that did not resolve
In addition, researchers investigating MT-II's libido-boosting effects may administer 1-2mg/day up to four times a month, with at least 48 hours in between administrations [22, 19]
Furthermore, the market is experiencing strong momentum due to advancements in drug delivery technologies, particularly the emergence of longeracting formulations
Effects of L-carnitine on ventricular arrhythmias in dogs with acute myocardial ischemia and a supplement of excess free fatty acids
Yes, Ro provides access to GLP-1s and Sparks, exclusive treatment options for weight management and sexual health, through its online platform